Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2000 Jan;29(1):31-4.
doi: 10.1093/ageing/29.1.31.

A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients

Affiliations
Clinical Trial

A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients

J Gedge et al. Age Ageing. 2000 Jan.

Abstract

Objectives: To compare a new low-dose warfarin induction regimen with the Fennerty regimen in elderly inpatients.

Design: Age-stratified, randomized prospective study.

Subjects: 120 age-stratified elderly inpatients.

Interventions: Each patient was randomized to either the new induction regimen or to a modified Fennerty regimen.

Main outcomes measures: Days to therapeutic International Normalized Ratio (INR >2); days in the therapeutic range (INR 2-3) during induction; number of patients with INR >4.5; ability of day 4 INR to predict day 8 warfarin dose.

Results: The mean time to therapeutic INR was longer for the new induction regimen than modified Fennerty regimen in patients aged 65-75 years [4.6 (mean) +/- 1.6 (SD) days vs 3.8 +/- 0.8 days; P = 0.03] and in patients aged >75 years (4.5 +/- 1.4 days vs 3.5 +/- 0.7 days; P = 0.003). Patients spent more time in the therapeutic INR range with the new induction regimen [3.0 +/- 1.3 days vs 2.7 +/- 1.3 days (P = 0.03) for those aged 65-75 years and 2.9 +/- 1.1 days vs 2.4 +/- 1.3 days (P = 0.04 for those aged >75 years]. Fewer patients using the new regimen had INRs >4.5 in the first 8 days [1 (3%) vs 6 (20%) for 65-75 years (P < 0.05) and 1 (3%) vs 11 (37%) for >75 years (P < 0.01)]. The ability to predict the maintenance dose to within 1 mg was 55% for both regimens.

Conclusion: The low-dose regimen has important clinical advantages over the Fennerty regimen for anticoagulating elderly inpatients.

PubMed Disclaimer

Comment in

LinkOut - more resources